ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Insilico Analysis of CYP17A1 in the Pathogenesis of Polycystic Ovarian Syndrome by Molecular Dynamics and Genotypic Characterization.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CYP17A1 gene (Cytochrome P45017A1) plays a significant role in the steroidogenic pathway that synthesizes sex steroids and glucocorticoids. In Cytochrome P45017A1, the heme-binding domain region is essential for its catalytic function to synthesize steroids. Mutations in the CYP17A1 gene have been associated with several pathological conditions, including congenital adrenal hyperplasia, Polycystic Ovary Syndrome (PCOS), now referred to as Polyendocrine Metabolic Ovarian Syndrome (PMOS), and certain types of cancers. This study aimed to identify deleterious missense mutations in CYP17A1 using in silico tools, molecular dynamics simulations, and genotyping to detect both rare and common variants. In silico analyses identified 22 pathogenic mutations using sequence- and structure-based tools. Furthermore, the mutations in the heme-binding domain (F453S, R449C) were characterized using molecular dynamics simulations. Results of Molecular dynamics simulations show that CYP17A1 mutants exhibit significant structural changes, particularly in the heme and steroid-binding regions, which weaken heme coordination and alter heme affinity. Based on the high minor allele frequency (MAF) of 0.04% in the South Indian population, the common variant rs743572 was genotyped in a cohort of (n = 100 PMOS cases and n = 90 healthy controls) to assess its population distribution and potential regulatory role in hormone-related disorders. These changes indicate functional impairments in steroidogenesis, informing the development of targeted therapies for related disorders. Thus, our findings offer valuable insights into the genetic basis of CYP17A1 dysregulation and highlight the need for precision medicine in targeting therapeutics for related disorders.
Indexed as
Identifiers
42920065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.